Startup Valuation Methods Explained: Which One Investors Trust

Two founders raised money last quarter. Same industry, same round size, same investor pool. One closed at an $8M post-money valuation. 

The other closed at $11.2M, according to a case referenced in Spectup’s 2026 valuation guide. 

Nothing about their businesses explains that 40% gap on its own. What explains it is that one founder walked in with a defensible valuation method and the other walked in with a number they picked because it sounded round.

That’s the part nobody tells you about startup valuation. It’s not a formula you plug numbers into and get a single correct answer from. 

It’s a negotiation, and the method you use to arrive at your number is what determines whether investors take that number seriously or quietly discount it the moment you leave the room.

So let’s go through the methods that actually show up in real term sheets in 2026, which ones investors trust at which stage, and where founders keep getting it wrong.

Why There’s No Single “Right” Method

If you’ve been searching for the one correct way to value a startup, here’s the uncomfortable answer: it depends entirely on your stage. A pre-revenue company with no customers can’t be valued with a discounted cash flow model, there’s no cash flow to discount. 

A Series B company with three years of revenue history shouldn’t lean on the Berkus method, that method was built for exactly the situation this company has already outgrown.

Waveup’s 2026 valuation guide, based on work advising over 600 startups and supporting more than $3B raised, puts it plainly: the most common mistake they see every quarter is a founder defaulting to the method they remember from business school, usually DCF, for a pre-seed round where it has no business being used. 

The fix isn’t picking a better single method. It’s triangulating two or three stage-appropriate methods and defending the range with real comparable data.

Here’s how that breaks down by stage.

Pre-Revenue Stage: Berkus Method and Scorecard Method

If you have a prototype and a team but no paying customers yet, these are the two methods angels and early investors actually run.

The Berkus Method, created by angel investor Dave Berkus, assigns a dollar value, up to $500,000 each, to five specific risk-reducing factors: a sound idea, a working prototype, a strong team, strategic relationships, and early sales or rollout. 

That caps a pre-revenue valuation at $2.5M under the original framework, according to ICanPitch’s breakdown of pre-revenue valuation methods. Some investors now use modified versions with higher factor values to reflect current market conditions, but the underlying logic stays the same: you’re not being valued on revenue you don’t have. You’re being valued on how many specific risks you’ve already removed.

The Scorecard Method, sometimes called the Bill Payne method, works differently. Instead of assigning fixed dollar amounts, it starts with the average pre-money valuation of comparable startups in your region and stage, then adjusts that baseline up or down based on how your company compares across factors like team strength, market size, and competitive environment, per Allied Venture Partners’ comparison of valuation models.

Here’s a real worked example from Virtue CPAs’ 2026 guide: a fintech startup founded by two former JPMorgan engineers, with a working MVP and a letter of intent from one regional bank, scored roughly $500,000 for its sound idea and $400,000 for strategic relationships under the Berkus framework. But the guide is direct about the limitation: given the size of the payment infrastructure opportunity and the strength of the team, institutional investors in the real world might value that same company at $6M to $10M, well above what Berkus alone produces. 

That’s exactly why Berkus rarely gets used alone. It’s a floor, not a ceiling, and it’s almost always paired with Scorecard or comparables to sanity-check the number.

Seed Stage: Risk Factor Summation and the VC Method

Once you have some traction but not yet a full revenue history, two methods take over.

Risk Factor Summation starts with a base valuation and adjusts it up or down across roughly twelve specific risk categories (management, stage of business, legislative risk, competition, and so on), giving you a more granular picture than Berkus alone, per ICanPitch’s guide.

The VC Method flips the whole exercise around. Instead of building up from your current assets, it starts with your projected exit value and works backward: post-money valuation equals projected exit value divided by the investor’s expected return multiple. 

According to Ascend Valuations’ 2026 breakdown, typical return expectations investors use in that formula run 20x to 30x for seed-stage investments and 10x to 15x for Series A. This method is popular precisely because it mirrors how an investor is actually thinking: not “what is this worth today” but “what does this need to return for the math on my fund to work.”

For context on what “typical” looks like at seed right now: NVCA data cited by Virtue CPAs puts average seed-stage pre-money valuations at $8M to $12M for rounds with an institutional lead investor. If your number is far outside that range, you’d better have a specific reason ready before an investor asks.

Series A and Beyond: DCF and Comparables

Once you have real revenue and a defensible growth trajectory, the conversation shifts to Discounted Cash Flow analysis and market comparables, the same tools used to value mature companies, adapted for growth-stage assumptions.

This is also where SaaS revenue multiples become the anchor for the comparables side of the equation, and the 2026 numbers matter here because a lot of founders are still pitching with 2021 comps. 

According to Aventis Advisors’ SaaS multiples tracker, the median SaaS revenue multiple fell to a low of 2.9x in 2024, rebounded to 3.8x in 2025, and had fallen again to 3.1x as of March 2026. Public SaaS companies currently trade at a median of roughly 6x to 7x EV/Revenue, per ScaleWithCFO’s 2026 data, while private companies typically trade at a 20-40% discount to that public benchmark due to illiquidity and information risk.

The spread within that range is not random. Livmo’s 2026 SaaS valuation report found that companies scoring above 50 on the Rule of 40 (growth rate plus profit margin) while maintaining net revenue retention above 120% were closing private transactions at 7x to 9x ARR, and that companies combining 60%+ growth with 130%+ NRR and competing strategic buyers reached 10x to 12x ARR, though that top tier represents fewer than 5% of private deals. 

If you’re building your comparables case, net revenue retention is doing more work than almost any other single number in the room.

The One Mistake That Discounts Your Credibility Instantly

Across every source, one warning shows up repeatedly: a suspiciously clean, round valuation is itself a red flag. Spectup’s 2026 guide puts it directly: a clean $5M ask reads as a number nobody actually calculated, while a defended range like $4.2M to $5.8M, tied to specific risk appetite and exit assumptions, reads as a number someone actually built.

That single distinction is often the real difference between the founder who gets a term sheet and the founder who gets a polite pass. Investors aren’t looking for the exact “right” number, because there isn’t one. 

They’re looking for evidence that you understand your own business well enough to defend whatever number you land on.

A Quick Reference: Which Method for Which Stage

• Idea to MVP, no customers: Berkus Method, cross-checked with Scorecard
• Some traction, pre-revenue or early revenue: Risk Factor Summation, paired with VC Method
• Series A, real revenue history: VC Method paired with Comparables
• Series B and beyond, 3+ years of revenue: DCF as the primary method, Comparables as the sanity check

Two methods, always. Never one. A single method gives you a number. Two methods that land in the same range give you a defensible range, and a defensible range is what actually survives a negotiation.

The Bottom Line

Startup valuation isn’t a math problem with one right answer waiting to be found. It’s a negotiation, and the method behind your number is the evidence you bring to that negotiation. 

Pick the wrong method for your stage, DCF at pre-seed, Berkus at Series B, and you don’t just get a worse number. You signal to the investor across the table that you don’t yet understand how this works, and that costs you leverage before the conversation even starts.

Know your stage. Triangulate two methods. Bring the comps. Defend the range, not a single number.

If you’re heading into a fundraising conversation and want a valuation model that will actually hold up under investor scrutiny, that’s exactly the kind of work we do at Stravyn Hill. Build the range before you walk into the room, not after someone challenges your number.